inhibitor therapy
Recently Published Documents


TOTAL DOCUMENTS

2992
(FIVE YEARS 874)

H-INDEX

98
(FIVE YEARS 19)

2021 ◽  
Author(s):  
Priya Nidamanuri ◽  
Jan Drappatz

Abstract Introduction: Meningiomas that progress after surgery and radiotherapy represent an unmet medical need. Expression of PD-1 and PDL-1 has been demonstrated in meningiomas and is proportional to tumor grade, suggesting a potential role for anti-PD-1/anti-PDL-1 inhibitor therapy. We explored the efficacy of immune checkpoint inhibitor therapy for recurrent meningiomas with primary endpoints of progression-free survival (PFS) and overall survival (OS).Methods: This is a retrospective chart review of patients with meningioma who were treated with PD-1 inhibitors at UPMC Hillman Cancer Center. Any patient over age 18 who received immunotherapy was included in this study. Patients received treatment until development of disease progression, intolerable toxicities or adverse events, death, or oncologist decision. Serial radiographic assessments were made every 3-6 months.Results: Between January 2015 and November 2021, eight patients received anti-PD-1 therapy. All patients underwent tumor resection and radiosurgery, and four patients received prior systemic therapy. Six out of eight patients experienced symptomatic perilesional edema and three patients experienced exacerbation of seizures. Median PFS was 7 months (95% CI 1-24) and median OS was 1.75 years (95% CI 1.5-4.0). In patients with positive PD-1 or PD-L1 expression, median PFS was 2 years and median OS was 3 years.Conclusion: Anti-PD-1 therapy was associated with a manageable safety profile in patients with recurrent meningiomas. Patients with WHO Grade III tumors and positive PD-1/PD-L1 expression were noted to have increased PFS and OS, suggesting a potential role for immunotherapy in this specific subset of patients. Further studies are needed to investigate this in a larger patient population.


2021 ◽  
Vol 12 ◽  
Author(s):  
Qingyi Wang ◽  
Bin Xie ◽  
Shuang Liu ◽  
Ying Shi ◽  
Yongguang Tao ◽  
...  

The fruitful results of tumor immunotherapy establish its indispensable status in the regulation of the tumorous immune context. It seems that the treatment of programmed cell death receptor 1 (PD-1) blockade is one of the most promising approaches for cancer control. The significant efficacy of PD-1 inhibitor therapy has been made in several cancer types, such as breast cancer, lung cancer, and multiple myeloma. Even so, the mechanisms of how anti-PD-1 therapy takes effect by impacting the immune microenvironment and how partial patients acquire the resistance to PD-1 blockade have yet to be studied. In this review, we discuss the cross talk between immune cells and how they promote PD-1 blockade efficacy. In addition, we also depict factors that may underlie tumor resistance to PD-1 blockade and feasible solutions in combination with it.


Cureus ◽  
2021 ◽  
Author(s):  
Chisato Agata ◽  
Kohdai Kitamoto ◽  
Kohei Ueda ◽  
Keiko Azuma ◽  
Tatsuya Inoue ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document